Results 41 to 50 of about 677,503 (281)

Resistance to Somatostatin Analogs in Acromegaly [PDF]

Endocrine Reviews, 2010
Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant treatment after surgery. First-line treatment with these drugs is generally used in the patients with macroadenomas or in those with clinical conditions so severe as to prevent unsafe reactions during anesthesia.
Colao, Annamaria, Auriemma, Renata S., Lombardi, Gaetano, Pivonello, Rosario   +3 more
openaire   +4 more sources

Pasireotide for the Medical Management of Feline Hypersomatotropism [PDF]

, 2015
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
Abraham, Adams, Alt, Appleton, Bhayana, Bruns, Castillo, Church, Colao, Colao, Cuevas-Ramos, Fedele, Fernandez-Rodriguez, Fougner, Golor, Henry, Hofland, Juul, Katznelson, Kvols, Lamb, Lamberts, Maxwell, Meij, Miller, Murray, Myers, Niessen, Niessen, Niessen, Niessen, Petrus, Polska, Rand, Ray, Schmid, Schmid, Sheppard, Slingerland, Sohmiya, Starkey, Stolk, Taboada, Wajchenberg, Zatelli, Zou   +45 more
core   +2 more sources

E-cadherin expression is associated with somatostatin analogue response in acromegaly [PDF]

, 2018
Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs)
Cano, David A., Castaño, Justo P., Dios, Elena, Flores Martínez, Álvaro, Ibáñez Costa, Alejandro, Japón Rodríguez, Miguel Ángel, Luque, Raúl M., Madrazo Atutxa, Ainara, Soto Moreno, Alfonso Manuel, Venegas Moreno, Eva, Vázquez Borrego, Mari C.   +10 more
core   +1 more source

Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study [PDF]

, 2019
Artículo escrito por un elevado número de autores, sólo se referencian el que aparece en primer lugar, y los autores pertenecientes a la UAMSomatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well ...
Carmona Bayonas, Alberto, Marazuela, Mónica   +1 more
core   +1 more source

Carcinoid Heart Disease: How to Diagnose and Treat in 2020?

Clinical Medicine Insights: Cardiology, 2020
Neuroendocrine tumors (NETs, originally termed “carcinoids”) create a relatively rare group of neoplasms with an approximate incidence rate of 2.5 to 5 cases per 100 000 persons.
Barbara Bober, Marek Saracyn, Maciej Kołodziej, Łukasz Kowalski, Elżbieta Deptuła-Krawczyk, Waldemar Kapusta, Grzegorz Kamiński, Olga Mozenska, Jacek Bil   +8 more
doaj   +1 more source

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly [PDF]

, 2016
PURPOSE: Cushing’s disease (CD) and acromegaly are characterized by excessive hormone secretion resulting in comorbidities such as impaired glucose metabolism, diabetes and hypertension.
Silverstein, Julie M
core   +2 more sources

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly

Journal of the Formosan Medical Association, 2016
The aim of the present study was to evaluate the serial changes of GH and IGF-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (LAR) and octreotide LAR.
Jan-Shun Chang, Ham-Min Tseng, Tien-Chun Chang   +2 more
doaj   +1 more source

Progress in the formulation and delivery of somatostatin analogs for acromegaly.

Therapeutic delivery, 2017
A 14 amino acid cystin bridge containing neuropeptide was discovered in 1973 and designated as growth hormone-inhibiting hormone, in other words, somatostatin.
Sarinj Fattah, David J Brayden
semanticscholar   +1 more source

Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging?

Genel Tıp Dergisi, 2022
Objective: Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor ...
Çağlagül Erol, Ahmet Volkan Çelik, Özlem Şahin, Gonca Kara Gedik, Hasan Önner, Farise Yılmaz   +5 more
doaj   +1 more source

Characterization of Somatostatin Receptor Subtype 2 Expression in Stably Transfected A-427 Human Cancer Cells

Molecular Imaging, 2007
Although radiolabeled somatostatin analogs have become highly prevalent in the diagnosis and treatment of somatostatin receptor subtype (sst)-positive tumors, there are relatively few options with respect to sst-positive tumor cell lines and animal ...
Jesse J. Parry, Martin Eiblmaier, Rebecca Andrews, Laura A. Meyer, Ryuji Higashikubo, Carolyn J. Anderson, Buck E. Rogers   +6 more
doaj   +1 more source